Autoantibody profile in children with Kawasaki disease on long‐term follow‐up: A prospective study from North India
Aim To study the profile of autoantibodies on long‐term follow‐up of children with Kawasaki disease (KD). Patients and methods In this single‐center observational cohort study, 50 children who had been diagnosed and treated for KD with a minimum follow‐up period of 3 years were enrolled. The organ‐s...
Saved in:
Published in | International journal of rheumatic diseases Vol. 21; no. 11; pp. 2036 - 2040 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.11.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aim
To study the profile of autoantibodies on long‐term follow‐up of children with Kawasaki disease (KD).
Patients and methods
In this single‐center observational cohort study, 50 children who had been diagnosed and treated for KD with a minimum follow‐up period of 3 years were enrolled. The organ‐specific autoantibodies that were assessed in the study included anti‐thyroid microsomal antibody (TMA), anti‐parietal cell antibody (PCA) and anti‐liver kidney microsomal (LKM) antibody. The organ‐nonspecific autoantibodies that were studied included anti‐endothelial cell antibody (AECA), anti‐nuclear antibody (ANA), anti‐neutrophil cytoplasmic antibody (ANCA), anti‐mitochondrial antibody (AMA) and anti‐smooth muscle antibody (SMA).
Results
The sample for assessment of serology was taken at a mean follow‐up period of 6.41 years (±1.95 SD) after diagnosis. Autoantibodies were detected in 11/50 (22%) patients. ANA was detected in three patients, TMA was positive in seven and ANCA was positive in one.
Conclusions
These autoantibodies likely develop in children with KD during the acute stage and may persist for many years. There is no concrete evidence to suggest that these children are at increased risk of developing an autoimmune disease in the future. However, there is some justification for prolonged surveillance for development of autoimmune manifestations. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 1756-1841 1756-185X |
DOI: | 10.1111/1756-185X.13372 |